Question 1

What's better, Dihexa or Semax?

Accepted Answer

Neither, on the evidence, because nothing has measured them against each other. Which is better would need a study giving each to comparable animals or people and scoring the same outcome, and no such study appears among the research behind this page. The only source that names both is a 2026 orthopaedic review, which says that neuroactive peptides like selank, semax, and dihexa enhance brain-derived neurotrophic factor and HGF/c-Met pathways critical to neuroplasticity, the brain's ability to rewire. That sentence groups them; it does not compare them. What a reader can compare is the stage each has reached. Semax has small human studies behind it, mostly Russian, set out on the Semax overview. Dihexa has none among the studies we could find. That is a difference in how much is known, not proof that one works better, and it is the honest basis for any choice between them.

Question 2

How do Dihexa and Semax compare side by side?

Accepted Answer

Set next to each other on what was studied, how strong the evidence is, and how each is given, the two look like compounds from different eras. Dihexa was studied for memory loss in Alzheimer's and Parkinson's models, plus single experiments on hearing damage in fish and nerve repair in rats. Its evidence is animal and cell work only. In rodents it was given mostly by mouth. It was built to answer a specific problem a 2013 review set out: there is a need for the development of analogs capable of penetrating the blood-brain barrier, meaning molecules that can get from the blood into the brain. Semax, by our own account on its hub page, was studied mainly in stroke, with one non-randomised study of 110 patients and two placebo-controlled imaging studies in healthy volunteers. Its regulatory standing differs too: Russian clinical publications describe it as a medicine in use there, while Dihexa never left the laboratory in the research behind this page.

Question 3

Do Dihexa and Semax work the same way?

Accepted Answer

Not on the proposed accounts. The two are linked to different growth signals in the brain. For Semax, the human stroke study measured BDNF, a protein that helps nerve cells survive and grow, as set out on the Semax overview. For Dihexa, the 2015 zebrafish paper describes a different idea: as a synthetic HGF mimetic, it forms a functional ligand by dimerizing with endogenous HGF to activate the HGF receptor, meaning it pairs with the body's own growth factor to switch on its receptor. The paper that first reported that dihexa binds with high affinity to hepatocyte growth factor, however, was retracted in 2025, and the account above rests partly on that withdrawn work. So the honest comparison is between one mechanism measured in human blood after stroke and another proposed in animals and dishes whose founding paper is gone. Those are different things, and neither tells a reader what either compound does to a healthy brain.

Question 4

Which cognitive peptide has the strongest evidence?

Accepted Answer

That depends on what counts as evidence, and the useful ladder is simple. A controlled human trial sits at the top, an uncontrolled human study below it, and animal work below that. Dihexa's whole family sits on the bottom rung: a 2018 systematic review limited to experimental, non-human studies of angiotensin IV and its relatives reports that of 450 articles identified, 32 met inclusion criteria. Semax reaches the middle rung, with small human studies, and Selank, the third compound the 2026 review groups with them, is covered on the Selank overview. None of that is a ranking of which one works. A compound with more human data is better understood, which is not the same as better. A reader looking for the strongest cognitive peptide is really asking which claims have been tested in people, and among these three, Dihexa's have not.

Question 5

How does Dihexa compare with Cerebrolysin and other nootropic peptides?

Accepted Answer

None of the studies behind this page mentions Cerebrolysin, so no comparison of its evidence with Dihexa's can be drawn from them. Its own record is set out on the Cerebrolysin overview. What can be said is what kind of thing Dihexa is, which is the first question to ask of any pairing. It is a single, small, made-to-order molecule with a defined structure, designed to be swallowed and to reach the brain. A reader weighing it against any other nootropic should ask the same three questions of both: has it been given to people, was there a control group, and what exactly was measured. Selank appears in the 2026 review alongside the other two, but beyond that grouping none of these sources sets Dihexa against Selank or any other nootropic peptide in an experiment. Every comparison a reader meets online between them is a comparison of claims rather than of results.

Question 6

How does Dihexa compare with angiotensin IV, the fragment it came from?

Accepted Answer

Dihexa is a cut-down, armoured version of a natural hormone fragment, and the differences are the point of it. The 2013 rat paper started from an earlier finding that the core structural information required to impart the procognitive activity of the AngIV analog, norleucine(1)-angiotensin IV, resides in its three N-terminal amino acids, Nle-Tyr-Ile, meaning the memory effect sat in just three building blocks. The developers kept two of those and added chemical caps so the molecule would last. The parent fragment itself has recently been tested over a longer span: in a 2025 mouse study, HGF, c-MET, or PAI-1 expression levels in the heart were not affected by AngIV treatment in mice given it for four weeks. That finding concerns the heart and the natural fragment, not Dihexa. It is a reminder that results for one member of this family cannot be carried to another without a study of the one in question.

Question 7

Are norleual, divalinal and 6-AH the same kind of compound?

Accepted Answer

They come from the same family and the same research, but they were built to do the opposite of Dihexa. A 2012 rat study describes divalinal as a potent inhibitor of the hepatocyte growth factor (HGF)/c-Met receptor system, the system Dihexa is meant to switch on. A 2019 review explains the purpose in cancer research: we have developed AngIV-based analogs designed to block dimerization of HGF and MSP and thus receptor activation. A retracted 2012 paper reported that its family of blockers binds directly to hepatocyte growth factor (HGF) and inhibit HGF's ability to form functional dimers. The zebrafish study used one of these, 6-AH, to cancel Dihexa's effect. That a few atoms separate a booster from a blocker is the strongest reason to care what is actually in a vial sold under the name.

Question 8

How does Dihexa compare with HGF itself?

Accepted Answer

Hepatocyte growth factor is a natural protein, and Dihexa was meant to do part of its job in a form that could be swallowed. The zebrafish paper puts the difference in one line: unlike native HGF, Dihexa is chemically stable and blood-brain barrier permeable. The retracted 2014 paper had reported that dihexa and Nle(1)-AngIV induce hippocampal spinogenesis and synaptogenesis similar to HGF itself, meaning new spines and connections on nerve cells in the memory centre of rodent brains. With that paper withdrawn, the claim that Dihexa reproduces what the natural protein does to nerve cells is weaker than it was. The stability and brain entry are still described in papers that stand, so the case for Dihexa over the protein is about getting into the brain rather than doing more once there.

Question 9

Are there other compounds that act on the same growth system?

Accepted Answer

Yes, and one recent paper shows why names matter when reading this research. A 2025 brain-injury study reports that, following repeated mild TBI, the HGF/MET-positive modulator dose-dependently rescued the working memory deficits following injury in a closed-head impact model. TBI is traumatic brain injury. The abstract does not name the molecule, so it cannot be counted as a Dihexa result, even though it turns up in searches alongside Dihexa and acts on the same receptor. That is a useful caution for anyone who meets this paper quoted as Dihexa evidence. A compound that works through the same receptor is a relative, not a substitute, and the zebrafish work shows how a small change in structure can change the effect. Each molecule has to carry its own evidence.

Question 10

Is Dihexa the same as the diHexa in other papers?

Accepted Answer

No. The name turns up in chemistry papers that have nothing to do with memory, and a reader searching medical databases will meet them. A 2007 skin cancer imaging paper in mice tested a tracer it calls DOTA-diHexa(NC-NC)-amide, built to carry a radioactive tag to tumour cells. There, diHexa is short for two six-part hormone pieces joined into one. It shares letters with Dihexa and that is all it shares. A 1992 rabbit lung study uses 1,2-dihexa-decyl-sn-glycero-3-phosphocholine, a fat whose long chemical name just happens to hold the same letters. Neither has any connection to the memory compound. A result from either cannot be cited as Dihexa evidence, and a product listing that does so has confused a name with a molecule.

Question 11

Has Dihexa been combined with other compounds?

Accepted Answer

Once in an animal study, and never with another nootropic among the research behind this page. The 2021 rat nerve study investigated whether administration of mesenchymal stem cell (MSC), Granulocyte-Colony Stimulating Factor (G-CSF) and/or Dihexa can improve recovery of limb function, running ten groups in different combinations. Stem cells from bone marrow and a blood-cell growth signal are not things a reader stacks at home, and the abstract does not separate what Dihexa added on its own from what the combinations did. In cell biology, Dihexa is also mixed with other small molecules as a lab recipe for growing liver-like cells, described on the Dihexa safety page. Neither use resembles the stacks discussed online.

Question 12

Can Dihexa and Semax be taken together?

Accepted Answer

No study among these sources gave the two together to any animal or person, so there is no record of what the pair does, good or bad. The question usually rests on the idea that two growth signals are better than one: BDNF from Semax and hepatocyte growth factor from Dihexa. That is a reasonable-sounding mechanism and nothing more. Neither compound's mechanism is settled, and Dihexa's founding paper on its own has been retracted. What a reader would be combining is one compound with small human studies and one with none, with no data among these sources on how they interact. The interaction record that does exist for Dihexa, from a single fish experiment, is on the Dihexa safety page, and the amounts given to animals are on the Dihexa dosage page. A combination that has not been studied is not the same as one known to be harmless.

Question 13

What would a fair comparison need?

Accepted Answer

More than either compound's research has produced so far. A fair test would give Dihexa, Semax and a dummy treatment to comparable groups of people, without anyone knowing who got which, and score the same outcome over the same time. It would use material checked for identity and strength, and record side effects as carefully as benefits. Short of that, a fair comparison at least needs both compounds tested in the same animal model by the same group. Even that step is missing among the research behind this page. Until one of those exists, every claim that one of these is stronger, faster or safer than the other is a claim about marketing rather than a measured result. The useful comparison is the one on this page: what each has been tested on, in what, and how far toward people each has got.

Dihexa comparisons and stacks